Form 13-F position report

AMYLYX PHARMACEUTICALS INC

Reported by PERCEPTIVE ADVISORS LLC

AMLX CUSIP 03237H101 Manager CIK 0001224962

Reported 10,573,735 shares, up 2,238,853 (26.9%) from the prior quarter.

Reported value 105.5%; share count 26.9% vs. the prior quarter.

Added
% of reported 13F value 5.36% This manager · Q3 2026
Shares 10,573,735 Quarter-end amount reported
Reported value $307,695,689 Fair value at quarter end
Consecutive quarters held 19 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-03-31 18942000
2022-06-30 68188000
2022-09-30 154038000
2022-12-31 224963904
2023-03-31 177056455
2023-06-30 105130433
2023-09-30 49233265
2023-12-31 27513520
2024-03-31 852000
2024-06-30 0
2024-09-30 6887103
2024-12-31 25607035
2025-03-31 27875192
2025-06-30 50654160
2025-09-30 121662640
2025-12-31 100081375
2026-03-31 115159860
2026-06-30 149694481
2026-09-30 307695689

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for AMYLYX PHARMACEUTICALS INC held by PERCEPTIVE ADVISORS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 10,573,735 +2,238,853 (26.9%) 5.36% $307,695,689 2026-11-16
Q2 2026 Added 8,334,882 +50,000 (0.6%) 2.25% $149,694,481 2026-08-14
Q1 2026 Unchanged 8,284,882 0 (0.0%) 2.25% $115,159,860 2026-05-15
Q4 2025 Reduced 8,284,882 -667,483 (-7.5%) 1.78% $100,081,375 2026-02-17
Q3 2025 Added 8,952,365 +1,050,000 (13.3%) 3.51% $121,662,640 2025-11-14
Q2 2025 Added 7,902,365 +28,017 (0.4%) 1.88% $50,654,160 2025-08-14
Q1 2025 Added 7,874,348 +1,100,000 (16.2%) 0.98% $27,875,192 2025-05-15
Q4 2024 Added 6,774,348 +4,648,699 (218.7%) 0.71% $25,607,035 2025-02-14
Q3 2024 New 2,125,649 +2,125,649 (0.0%) 0.15% $6,887,103 2024-11-14
Q2 2024 Reduced 0 -300,000 (-100.0%) 0 $0 2024-08-14
Q1 2024 Reduced 300,000 -1,569,125 (-83.9%) 0.01% $852,000 2024-05-15
Q4 2023 Reduced 1,869,125 -819,748 (-30.5%) 0.61% $27,513,520 2024-02-14
Q3 2023 Reduced 2,688,873 -2,185,046 (-44.8%) 1.64% $49,233,265 2023-11-14
Q2 2023 Reduced 4,873,919 -1,160,725 (-19.2%) 3.04% $105,130,433 2023-08-14
Q1 2023 Reduced 6,034,644 -53,689 (-0.9%) 5.23% $177,056,455 2023-05-15
Q4 2022 Added 6,088,333 +616,300 (11.3%) 6.32% $224,963,904 2023-02-14
Q3 2022 Added 5,472,033 +1,931,625 (54.6%) 4.47% $154,038,000 2022-11-14
Q2 2022 Added 3,540,408 +2,066,301 (140.2%) 2.14% $68,188,000 2022-08-15
Q1 2022 New 1,474,107 +1,474,107 (0.0%) 0.38% $18,942,000 2022-05-16

Who else reported the position

264 managers reported AMYLYX PHARMACEUTICALS INC for Q3 2026.

Managers reporting AMYLYX PHARMACEUTICALS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 19,945,501 +3,217,592 0.03% $580,414,080 19 qtrs
PERCEPTIVE ADVISORS LLC This report Added 10,573,735 +2,238,853 5.36% $307,695,689 19 qtrs
BlackRock Inc Added 10,368,007 +1,540,922 < 0.01% $301,709,016 9 qtrs
TCG Crossover Management LLC Unchanged 6,243,812 0 5.13% $181,694,929 9 qtrs
DRIEHAUS CAPITAL MANAGEMENT LLC Added 5,428,489 +2,391,519 1.1% $157,969,030 6 qtrs
JANUS HENDERSON GROUP PLC Added 5,400,720 +414,647 0.07% $157,034,186 1 qtr
VANGUARD CAPITAL MANAGEMENT LLC Added 5,077,511 +853,287 < 0.01% $147,755,570 3 qtrs
Saturn V Capital Management LLC Reduced 4,471,356 -152,745 19.05% $130,116,460 8 qtrs
RA CAPITAL MANAGEMENT L P New 4,279,341 +4,279,341 1.25% $124,528,823 1 qtr
First Light Asset Management LLC Added 3,986,548 +963,292 6.88% $116,008,547 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
10,573,735
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.